<DOC>
	<DOC>NCT00225186</DOC>
	<brief_summary>The purpose of this study is to demonstrate safety and efficacy of SH T00660AA for the treatment of endometriosis</brief_summary>
	<brief_title>Safety and Efficacy of SH T00660AA in Treatment of Endometriosis</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Female patients with endometriosisassociated pelvic pain Pregnant or lactating women History or suspicion of hormone dependent tumor Therapy resistant endometriosis or need for primary surgical treatment Any other conditions which forbid the participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>